Market Place
Sourcing Support
Jazz plots massive growth for UK cannabinoid operations
29 Mar 2022 //
ENDPTS
Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing
24 Mar 2022 //
PRNEWSWIRE
GW Pharma gets nod for reimbursement of Epidyolex
17 Dec 2021 //
PHARMABIZ
Cannabidiol gains MHRA approval as adjunctive treatment of seizures
11 Aug 2021 //
PHARMA FILE
GW Pharma Sells for Billions; Psychedelic Company Following Similar Path
29 Jun 2021 //
PR NEWSWIRE
GW Pharma Sells for Billions; Psychedelic Company Following Similar Path
29 Jun 2021 //
PRNEWSWIRE
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
05 May 2021 //
PRNEWSWIRE
Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc
05 May 2021 //
BIOSPACE
GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals
23 Apr 2021 //
BIOSPACE
GW Pharma’s cannabidiol gains EC approval
21 Apr 2021 //
PHARMAFILE
GW Pharma’s Epidyolex scores new EU indication
20 Apr 2021 //
PHARMATIMES
GW and U.S. Subsidiary Greenwich Biosciences to Present Data at the 2021
13 Apr 2021 //
GWPHARM
Jazz CEO Bruce Cozadd campaigned for 6 months to buy GW Pharma. A 90%
05 Mar 2021 //
ENDPTS
Jazz Pharma to buy GW Pharma, maker of CBD-based epilepsy drug, for $7.2B
04 Feb 2021 //
BIOPHARMADIVE
PAOG Highlights Its Own Cannabis Pharma Tech As GW Pharma Valued At $7.2 B
03 Feb 2021 //
PRNEWSWIRE
Canopy Growth Files Patent Infringement Lawsuit Against GW Pharmaceuticals
24 Dec 2020 //
NASDAQ
Canopy Growth Files Patent Infringement Lawsuit Against GW Pharmaceuticals
24 Dec 2020 //
PATENTDK-NS
GW & U.S. Subsidiary Greenwich Biosciences to Present Epidiolex®
01 Dec 2020 //
GWPHARM
GW Pharma begins recruitment for US-based Sativex trial
04 Nov 2020 //
PHARMA TIMES
GW Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis
03 Nov 2020 //
PRESS RELEASE
Gilead submits filgotinib to European regulators for UC; GW launches PhIII trial
03 Nov 2020 //
ENDPTS
GW Pharmaceuticals receives TGA approval for EPIDYOLEX (cannabidiol)
22 Sep 2020 //
BIOSPACE
Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols
10 Sep 2020 //
BIOSPACE
FDA Approves EPIDIOLEX® (cannabidiol) Oral Solution to Treat Seizures
03 Aug 2020 //
PRESS RELEASE
GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy
30 Jun 2020 //
GLOBENEWSWIRE
Zogenix`s Fintepla ready to challenge GW Pharma in rare epilepsy
26 Jun 2020 //
FIERCEPHARMA
GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol)
23 Jun 2020 //
GLOBENEWSWIRE
Rett failure sets up thin pipeline
04 May 2020 //
EVALUATE
GW plc & Its U.S. Subsidiary Greenwich Biosciences Announce That EPIDIOLEX
06 Apr 2020 //
GLOBENEWSWIRE
GW Pharma regains Sativex rights in UK
03 Mar 2020 //
PHARMATIMES
Innovation`S Provides Scientific Rationale & Clinical Development for Brilacidin
02 Mar 2020 //
PREE RELEASE
Another hiccup for GW`s seizure drug rival, Zogenix discloses FDA review delay
27 Feb 2020 //
ENDPTS
1 Picture You Need to See Before Writing Off GW Pharmaceuticals
20 Jan 2020 //
THE MOOTLEY FOOL
NHS fast-tracks access to GW pharma`s Epidyolex for severe epilepsy
24 Dec 2019 //
PHARMA TIMES
Can Biohaven challenge the Allergan/AbbVie goliath in migraine?
03 Dec 2019 //
FIERCE PHARMA
Gilead’s converting Truvada PrEP users to Descovy faster than expected
03 Dec 2019 //
FIERCE PHARMA
NICE ‘OK’ for Sativex in MS
14 Nov 2019 //
PHARMA TIMES
NICE backs first cannabis-based drugs, both from GW Pharma
12 Nov 2019 //
PMLIVE
Can CBD temper Parkinson`s-related psychosis?
15 Oct 2019 //
ENDPTS
GW Pharma to launch first CBD-based epilepsy drug in Europe -over the next year
25 Sep 2019 //
CNBC
GW Pharma`s cannabis-derived medicine makes the cut in the European Union
24 Sep 2019 //
ENDPTS
GW Pharma`s Epidyolex (cannabidiol) Receives Approval in Europe
19 Sep 2019 //
EMA
Teva subsidiary inks deal with medical cannabis product maker
13 Sep 2019 //
FIERCE PHARMA
NICE to work with GW Pharma after Epidiolex rejection
27 Aug 2019 //
PHARMA TIMES
Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
23 Aug 2019 //
PMLIVE
GW Pharma CEO: More education needed on real health benefits of drugs
08 Aug 2019 //
CNBC
Marijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaring
07 Aug 2019 //
MARKETWATCH
FDA issues warning to CBD company Curaleaf
29 Jul 2019 //
PHARMAFILE
European panel okays GW Pharma cannabis drug for epilepsy
26 Jul 2019 //
REUTERS
Zogenix Ready to Resubmit Fintepla for Rare Epilepsy to FDA
27 Jun 2019 //
BIOSPACE
Cannabidiol shows promise against superbug infections
25 Jun 2019 //
FIERCE BIOTECH
GW Pharma takes physicians on VR “voyage” to marijuana greenhouse
18 Jun 2019 //
FIERCE PHARMA
GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy
07 May 2019 //
ENDPTS
GW Pharma announce Darren Cline as company`s new Chief Commercial Officer
12 Apr 2019 //
PHARMAFILE
GW Pharma announces sale of priority review voucher for $105 million
18 Mar 2019 //
MARKET WATCH
After November rollout, GW says Epidiolex positioned for strong growth
05 Mar 2019 //
FIERCE PHARMA
Early Epidiolex sales push up GW Pharma`s stock
28 Feb 2019 //
BIOPHARMA DIVE
GW Pharmaceuticals announce quarterly financial results
27 Feb 2019 //
PHARMA TIMES
The 2018 breakdown on a chart-topping set of new drug approvals
02 Jan 2019 //
ENDPTS
FSD Pharma scoops GW Pharma exec to guide cannabinoid development
29 Nov 2018 //
ENDPTS
